Navigation Links
Adjunctive rufinamide reduces refractory partial-onset seizures
Date:9/30/2010

Researchers from the Arkansas Epilepsy Program found treatment with rufinamide results in a significant reduction in seizure frequency compared with placebo, for patients with uncontrolled partial-onset seizures (POS). Details of this study are now available online in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy.

Epilepsy affects up to 2% of the worldwide population according to the Centers for Disease Control and Prevention. More than half of these patients experience POS, or focal seizures, which are initiated in one part of the brain. Despite an expanding number of antiepileptic drugs (AEDs) available to treat partial-onset epilepsy, about one-third of epilepsy patients remain resistant to available treatments and many more experience intolerable side effects, driving the search for therapeutic alternatives. The current study evaluated rufinamide, an AED with a novel triazole-derivative structure, to confirm its efficacy and safety at a dose of 1,600 mg twice daily as adjunctive treatment for refractory POS.

Eligible patients were male or female, aged 12-80 years, with POS with or without secondarily generalized seizures. Patients' seizures were inadequately controlled on stable doses of up to three concomitantly administered AEDs, with no evidence of AED treatment noncompliance. All medication taken regularly by patients, including AEDs, remained unchanged for at least 1 month prior to study start and throughout the study. Patients were enrolled at 61 centers in the U.S. and at four centers in Canada between February 2006 and March 2009. In total, 357 patients were randomly assigned to receive rufinamide (n = 176) or placebo (n = 181) and entered the titration phase, and 139 and 156 patients, respectively, completed the study. This study comprised a 56-day baseline phase (BP), 12-day titration phase, and 84-day maintenance phase (MP).

The researchers found that treatment with rufinamide resulted in a statistically significant reduction in total partial seizure frequency compared with placebo. Results also showed a 50% reduction in responder rate and total partial seizure frequency rate in patients treated with rufinamide. Several exploratory efficacy variables, including at least 75% responder rate and increase in the number of seizure-free days, were also associated with notably better results for rufinamide.

With respect to efficacy by seizure type, rufinamide was significantly superior to placebo for complex partial seizures, the most common seizure type, and numerically superior to placebo for simple partial seizures and secondarily generalized partial seizures. The median reduction in secondarily generalized partial seizures of 40% in this study is consistent with that previously observed at identical rufinamide dosage.

Study leader Victor Biton, M.D., comments, "Overall, there were no significant pharmacokinetic (PK) effects on either rufinamide or any second-generation AED when given with other medications." The research team confirmed PK results found in previous studiesshowing lower oral bioavailability of rufinamide at higher doses, increased clearance of rufinamide with increasing body weight, and no effect of prolonged rufinamide dosing on the PK of rufinamide."

"Our study demonstrates that rufinamide is effective as adjunctive therapy in reducing total partial seizure frequency in treatment-refractory adolescent and adult patients, and confirms the known safety and tolerability profile of rufinamide in this patient population," concludes Dr. Biton.


'/>"/>

Contact: Dawn Peters
healthnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. After traumatic event, early intervention reduces odds of PTSD in children by 73 percent
2. Nonstick coating of a protein found in semen reduces HIV infection
3. Smoked cannabis reduces chronic pain
4. Reminding health-care staff to remove catheters reduces infections by half
5. New drug reduces tumor size in women with advanced hereditary ovarian or breast cancer
6. Brain study shows that thinking about God reduces distress -- but only for believers
7. Teenage physical activity reduces risk of cognitive impairment in later life
8. Filtering donor blood reduces heart, lung complications
9. Lifestyle intervention reduces preschoolers body fat, improves fitness
10. Breast Milk Reduces Infections in Babies
11. Hopes Dashed That Vitamin D Reduces Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... , ... In sleep, when the defenses of the day are at rest, ... with eating disorders is significant self-criticism, and consequently these patients experience this disease with ... maladaptive means for coping with this unease, but also leads to a reservoir of ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... practical mobile kitchens, recently announced the debut of their latest mobile kitchen model, ... Kitchens provides organizations with modern, high-volume commercial kitchens for use anywhere in the ...
(Date:2/5/2016)... Moscow, Russia (PRWEB) , ... February 05, 2016 , ... ... update has a completely new user interface design and the developer has fixed known ... with those they want to on their phone while not consuming any of their ...
(Date:2/5/2016)... ... , ... –This week, Atascadero water heater company First Call Plumbing ... view the report, click here or see below. , There are ... and cons, the type chosen is almost entirely up to personal preference. However, tankless ...
(Date:2/5/2016)... ... ... tired of trying to cram belongings into spare space that just isn’t there, a self-storage ... before hastily spending money on a unit, take these tips into consideration. , Self-storage is ... often not told when utilizing these services are some tips on how to use the ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... For hospitals considering enrollment in the Federal ... the program, the Health Resources and Services Administration,s (HRSA) ... Mega-Guidance , could have significant impact on plans and ... 2016. Essential Insights , Daniel Neal, ... the Mega-Guidance,s key proposed changes, including a new requirement ...
(Date:2/4/2016)... 2016  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN ... into a settlement agreement with the United States ... SEC,s investigation into possible violations of the Foreign ... the settlement agreement, SciClone has agreed to pay ... interest and a penalty.  This payment is in ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Identifying and Commercializing First-in-Class Innovation ... disorder associated with chronic inflammation of the airways ... of COPD symptoms make the disease one of ... cause of death in the world. COPD is ...
Breaking Medicine Technology: